Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups.
Male
Humans
Prostate-Specific Antigen
Prostate
/ diagnostic imaging
Retrospective Studies
Urology
Progression-Free Survival
Gallium Radioisotopes
Positron Emission Tomography Computed Tomography
/ methods
Prostatectomy
Prostatic Neoplasms
/ diagnostic imaging
Positron-Emission Tomography
Neoplasm Recurrence, Local
/ pathology
PET/CT
PSMA
biochemical failure
prostate-specific membrane antigen
radical prostatectomy
salvage RT
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
04
08
2022
received:
23
09
2021
accepted:
27
04
2022
pubmed:
30
4
2022
medline:
25
11
2022
entrez:
29
4
2022
Statut:
ppublish
Résumé
To assess European Association of Urology (EAU) risk groups for biochemical recurrence (BCR) of prostate cancer relative to prostate-specific membrane antigen-positron emission tomography (PSMA-PET) status and oncological outcomes. A retrospective analysis of a study that incorporated PSMA-PET for men with BCR after radical prostatectomy (RP) was undertaken. EAU risk groups were considered relative to clinical variables, PSMA-PET findings, and deployment of salvage radiotherapy (SRT). The primary oncological outcome was event-free survival (EFS) and this was analysed relative to clinical and imaging variables. An 'event' occurred if prostate-specific antigen (PSA) level rose >0.2 ng/mL above nadir or additional therapies were introduced. A total of 137 patients were included, most of whom had EAU high-risk disease (76%) and/or low PSA levels (80% <0.5 ng/mL) at the time of PSMA-PET. EAU risk group was not associated with regional nodal/distant metastasis on PSMA-PET. Regional nodal/distant metastasis on PSMA PET (compared to negative/local recurrence: hazard ratio [HR] 2.2; P = 0.002) and SRT use (vs no SRT: HR 0.44; P = 0.004) were associated with EFS. EAU high-risk status was not significantly associated with worse EFS (HR 1.7, P = 0.12) compared to EAU low-risk status. Among patients who received SRT, both regional/distant metastasis on PSMA-PET (HR 3.1; P < 0.001) and EAU high-risk status (HR 2.9; P = 0.04) were independently associated with worse EFS, which was driven by patients in the EAU high-risk group with regional/distant metastases (38%; HR 3.1, P = 0.001). In patients with post-RP BCR, PSMA-PET findings and receipt of SRT predicted EFS. In patients receiving SRT, PSMA status combined with EAU risk grouping was most predictive of EFS. These findings suggest that the EAU risk groups could be improved with the addition of PSMA-PET.
Identifiants
pubmed: 35488182
doi: 10.1111/bju.15762
pmc: PMC9796546
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Gallium Radioisotopes
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
32-39Informations de copyright
© 2022 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International.
Références
Urol Oncol. 2021 May;39(5):298.e1-298.e6
pubmed: 33579626
J Urol. 2008 Nov;180(5):1980-4; discussion 1985
pubmed: 18801519
Eur Urol. 2021 Feb;79(2):263-282
pubmed: 33039206
Eur Urol. 2021 Mar;79(3):374-383
pubmed: 33293078
Prostate Cancer Prostatic Dis. 2014 Jun;17(2):174-9
pubmed: 24614692
Eur Urol. 2016 Apr;69(4):728-733
pubmed: 26497924
Eur Urol Focus. 2020 Mar 15;6(2):231-234
pubmed: 31248850
Eur Urol Focus. 2021 Mar;7(2):238-240
pubmed: 33386288
JAMA Oncol. 2021 Apr 1;7(4):544-552
pubmed: 33570548
Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2804-2815
pubmed: 32314028
Eur Urol. 2019 Jun;75(6):896-900
pubmed: 30955970
Lancet. 2020 Apr 11;395(10231):1208-1216
pubmed: 32209449
J Nucl Med. 2020 Jun;61(6):866-872
pubmed: 31676727
JAMA. 2004 Mar 17;291(11):1325-32
pubmed: 15026399
Eur Urol. 2019 Jun;75(6):967-987
pubmed: 30342843
Radiother Oncol. 2021 Jan;154:255-259
pubmed: 32920006
J Nucl Med. 2022 Feb;63(2):248-252
pubmed: 34326128
JAMA Oncol. 2019 Jun 01;5(6):856-863
pubmed: 30920593
Lancet. 2020 Oct 31;396(10260):1422-1431
pubmed: 33002431
BJU Int. 2021 Oct;128 Suppl 1:6-8
pubmed: 33977631
J Clin Oncol. 2016 Oct 20;34(30):3648-3654
pubmed: 27528718
Clin Exp Metastasis. 2020 Aug;37(4):551-560
pubmed: 32519046
Radiother Oncol. 2018 Nov;129(2):377-386
pubmed: 30037499
Lancet. 2021 May 22;397(10288):1895-1904
pubmed: 33971152
Eur J Nucl Med Mol Imaging. 2022 Jul;49(9):3289-3294
pubmed: 35298693
J Nucl Med. 2017 Dec;58(12):1972-1976
pubmed: 28747524